Comments to FDA: Evaluating Drug Names for Similarities Share page: Docket Number: 2003N-0201 Letter to Daniel E. Troy, Esq. regarding whether there should be different trade-name evaluation procedures for different classes of drugs (Rx versus OTC). Download Document Issues: OTC Medicines Other Issues Branding Related Posts Weekly Voice Federal Register (FR) Notices, Friday, May 27, 2022 May 25, 2022 Press Releases and Statements CHPA Reiterates Call for Additional Measures on Dietary Supplement Provisions in Draft User Fee Reauthorization Package May 18, 2022 Press Releases and Statements CHPA Statement on Recent Observational Study Related to Inflammation, Analgesics, and Chronic Pain May 17, 2022